Metastable Crystallins: Structure and Stabilization
亚稳态晶体蛋白:结构和稳定性
基本信息
- 批准号:8470982
- 负责人:
- 金额:$ 47.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-05-01 至 2018-04-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAdultAgingAlzheimer&aposs DiseaseBlindnessBody partCataractCataract ExtractionCell Culture TechniquesCellsClientComplexCrystallinsDataDegenerative DisorderDepositionDevelopmentDiabetes MellitusDiseaseEyeGlaucomaGoalsHumanHuntington DiseaseImplantInterventionIntraocular lens implant deviceInvestigationKnowledgeLeadLearningMalignant NeoplasmsMethodsModificationMolecular ChaperonesMutationNamesNuclearOrganParkinson DiseasePathogenesisPeptidesPlayProtein ConformationProteinsReagentRecoveryResearchRoleSavingsSiteSite-Directed MutagenesisStructureSystems AnalysisTestingTherapeuticTimeTissuesage relatedcostcrosslinkfunctional restorationinnovationinsightlenslens proteinlens transparencylight scatteringmacromoleculemutantnovelpeptide Apreventprotein aggregateprotein aggregationprotein misfoldingprotein protein interactionpublic health relevanceresearch studystemsynthetic peptidetool
项目摘要
DESCRIPTION (provided by applicant): Many diverse diseases, including cataract, some types of glaucoma, Alzheimer disease, diabetes and cancer to name only a few, are now known to share the common feature of aggregated, misfolded or modified protein deposits. The pathological hallmark in this group of diseases is protein aggregation and deposition in specific cells, tissues or organs. The pathological similarities indicate that common principles that govern protein interactions underlie protein misfolding degenerative diseases. Cataract is a classic example of a protein misfolding and aggregation disease. Cataract, a major cause of blindness in the world, develops as a result of age-related modifications and aggregation of the lens proteins. ?-crystallin accounts for nearly 40% of the adult lens proteins but its structure-function is yet to be fully understood. The chaperone-like activity of ?-crystallin is believed to play a central role in maintaining lens transparency. During aging, lens crystallins undergo truncation and these modifications correlate with lens crystallin aggregations responsible for light scattering. It is well established that the addition of ?-crystallin to aggregating proteins stops a further increase in aggregation and light scattering. We have demonstrated that specific sequences in ?-crystallin subunits suppress aggregation of denaturing proteins. However, the full potential of ?-crystallin-derived peptides (mini-chaperones) is yet to be realized. To enhance
our understanding of the role of non-native interactions in cataract formation, we propose the following specific aims: Aim 1. Identify the sequences involved in abnormal interactions of ?A-crystallin subunits that lead to protein aggregation in human cataract-causing ?A-crystallin mutants (?AR49C, ?AF71V, ?AG98R and ?AR116H) using novel deuterated cross linkers, biotynylated reagents and peptide arrays. Aim 2. Determine the mechanism and efficacy of ?A-crystallin-derived mini-chaperone in preventing the aggregation of metastable ?A- crystallins (mutants and truncated crystallins) and restoring chaperone activity. The specific aims will be accomplished using novel cross-linkers and mass spectrometric methods. We will also use site-directed mutagenesis and cell culture expression and analysis systems to confirm the cross linking data. These innovative studies will give us new insights into potential interventions for protein misfolding diseases, not only of the eye but also of other parts of the body.
描述(由申请人提供):现在已知许多不同的疾病,包括白内障、某些类型的青光眼、阿尔茨海默病、糖尿病和癌症,仅举几例,都具有聚集、错误折叠或修饰的蛋白质沉积的共同特征。这组疾病的病理学标志是蛋白质聚集和沉积在特定细胞、组织或器官中。病理学的相似性表明,共同的原则,管理蛋白质相互作用的蛋白质错误折叠退行性疾病的基础。白内障是蛋白质错误折叠和聚集疾病的典型例子。白内障是世界上致盲的主要原因,其发展是透镜蛋白质的年龄相关性改变和聚集的结果。?-晶状体蛋白占成人透镜蛋白质的近40%,但其结构-功能尚未完全了解。像监护人一样的活动?晶体蛋白被认为在保持透镜透明度中起中心作用。在老化过程中,透镜晶状体蛋白经历截短,并且这些修饰与负责光散射的透镜晶状体蛋白聚集相关。这是公认的,增加?晶状体蛋白与聚集蛋白质的结合阻止了聚集和光散射的进一步增加。我们已经证明了?-晶状体蛋白亚基抑制变性蛋白的聚集。然而,充分发挥潜力?堆叠衍生肽(小分子伴侣)还有待实现。加强
基于我们对白内障形成中非天然相互作用的理解,我们提出了以下具体目标:目标1。识别序列参与异常相互作用?A-晶状体蛋白亚基导致蛋白质聚集在人类白内障?A-晶体蛋白突变体(?AR49C,?AF71V,?AG 98 R和?AR116H)。目标二。确定的机制和疗效?A-晶状体蛋白衍生的微型分子伴侣在防止亚稳态聚集中的作用?A-晶体蛋白(突变体和截短晶体蛋白)和恢复伴侣活性。具体目标将使用新型交联剂和质谱方法来实现。我们还将使用定点诱变和细胞培养表达和分析系统来确认交联数据。这些创新的研究将为我们提供新的见解,以了解蛋白质错误折叠疾病的潜在干预措施,不仅是眼睛,而且是身体的其他部位。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KRISHNA K SHARMA其他文献
KRISHNA K SHARMA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KRISHNA K SHARMA', 18)}}的其他基金
Metastable Crystallins: Structure and Stabilization
亚稳态晶体蛋白:结构和稳定性
- 批准号:
9132472 - 财政年份:2013
- 资助金额:
$ 47.96万 - 项目类别:
Metastable Crystallins: Structure and Stabilization
亚稳态晶体蛋白:结构和稳定性
- 批准号:
10200048 - 财政年份:2013
- 资助金额:
$ 47.96万 - 项目类别:
Metastable Crystallins: Structure and Stabilization
亚稳态晶体蛋白:结构和稳定性
- 批准号:
8841373 - 财政年份:2013
- 资助金额:
$ 47.96万 - 项目类别:
Metastable Crystallins: Structure and Stabilization
亚稳态晶体蛋白:结构和稳定性
- 批准号:
10657220 - 财政年份:2013
- 资助金额:
$ 47.96万 - 项目类别:
Metastable Crystallins: Structure and Stabilization
亚稳态晶体蛋白:结构和稳定性
- 批准号:
9265858 - 财政年份:2013
- 资助金额:
$ 47.96万 - 项目类别:
Metastable Crystallins: Structure and Stabilization
亚稳态晶体蛋白:结构和稳定性
- 批准号:
8657443 - 财政年份:2013
- 资助金额:
$ 47.96万 - 项目类别:
Metastable Crystallins: Structure and Stabilization
亚稳态晶体蛋白:结构和稳定性
- 批准号:
9769023 - 财政年份:2013
- 资助金额:
$ 47.96万 - 项目类别:
Crystallin-Derived Anti-Chaperones in the Lens
晶状体中的晶状体蛋白衍生的反伴侣分子
- 批准号:
8306862 - 财政年份:2010
- 资助金额:
$ 47.96万 - 项目类别:
Crystallin-Derived Mini-Chaperones as Protein Aggregation Inhibitors
晶状体蛋白衍生的微型伴侣作为蛋白质聚集抑制剂
- 批准号:
7976444 - 财政年份:2010
- 资助金额:
$ 47.96万 - 项目类别:
Crystallin-Derived Anti-Chaperones in the Lens
晶状体中的晶状体蛋白衍生的反伴侣分子
- 批准号:
7992774 - 财政年份:2010
- 资助金额:
$ 47.96万 - 项目类别:
相似海外基金
Investigating HDAC3 phosphorylation as an epigenetic regulator of memory formation in the adult and aging brain
研究 HDAC3 磷酸化作为成人和衰老大脑记忆形成的表观遗传调节剂
- 批准号:
10752404 - 财政年份:2023
- 资助金额:
$ 47.96万 - 项目类别:
The Health of Aging Parents of Adult Children with Serious Conditions
患有严重疾病的成年子女的年迈父母的健康
- 批准号:
10660046 - 财政年份:2023
- 资助金额:
$ 47.96万 - 项目类别:
Understanding Longer-Living Older Adult Research: The Summer Program on Aging
了解长寿老年人研究:老龄化夏季项目
- 批准号:
476343 - 财政年份:2022
- 资助金额:
$ 47.96万 - 项目类别:
Role of sensory experience in the regulation of plasticity in the developing, adult and aging brain
感官体验在发育、成人和衰老大脑可塑性调节中的作用
- 批准号:
RGPIN-2019-04761 - 财政年份:2022
- 资助金额:
$ 47.96万 - 项目类别:
Discovery Grants Program - Individual
Adult Cognitive and Neurobiological Indicators of Aging: Impact of Adversity and Social Support
成人衰老的认知和神经生物学指标:逆境和社会支持的影响
- 批准号:
10365348 - 财政年份:2022
- 资助金额:
$ 47.96万 - 项目类别:
Adult Cognitive and Neurobiological Indicators of Aging: Impact of Adversity and Social Support
成人衰老的认知和神经生物学指标:逆境和社会支持的影响
- 批准号:
10700796 - 财政年份:2022
- 资助金额:
$ 47.96万 - 项目类别:
Endogenous barcoding to determine complex dynamics of adult neurogenesis in aging and Alzheimer's disease
内源条形码确定衰老和阿尔茨海默病中成人神经发生的复杂动态
- 批准号:
10651861 - 财政年份:2022
- 资助金额:
$ 47.96万 - 项目类别:
Investigating the interface of epigenetics and metabolism underlying memory formation in the adult, aging, and AD brain
研究成人、衰老和 AD 大脑中记忆形成的表观遗传学和代谢界面
- 批准号:
10420533 - 财政年份:2022
- 资助金额:
$ 47.96万 - 项目类别:
Endogenous barcoding to determine complex dynamics of adult neurogenesis in aging and Alzheimer's disease
内源条形码确定衰老和阿尔茨海默病中成人神经发生的复杂动态
- 批准号:
10846200 - 财政年份:2022
- 资助金额:
$ 47.96万 - 项目类别:
THE DEVELOPMENT OF MECHANISM-BASED ADULT STEM CELL TREATMENTS TO COMBAT AGING PATHOLOGIES
开发基于机制的成人干细胞疗法来对抗衰老病理学
- 批准号:
10721544 - 财政年份:2022
- 资助金额:
$ 47.96万 - 项目类别: